

National Institute for Health and Care Excellence

**Irritable Bowel Syndrome (Standing Committee A)  
Addendum Consultation Table  
29 October – 26 November 2014**

Type	Stakeholder	Order No	Document	Page No	Line No	Comments Please insert each new comment in a new row.	Developer's Response Please respond to each comment
SH	Almirall Ltd	1	Addendum	11	17	<p>To include in section "Key priorities for implementation", content consistent with the guidance provided on page 17 (section Recommendations), where linaclotide is recommended after laxatives have not helped.</p> <p>"Consider linaclotide for people with moderate or severe symptoms of IBS with constipation only if: 1) They have had IBS symptoms for at least 12 months and 2) optimal or maximum tolerated doses of laxatives have not helped." [2015]</p>	<p>Thank you for your comment. The KPIs specified in the original NICE guideline were prioritised from all the recommendations by the original guideline development group in 2008. It is outside the remit of this particular update to re-prioritise previous KPIs</p> <p>Thank you for your comment. The Committee discussed this recommendation wording and made some amendments. The updated recommendation reads as follows:</p> <p><b>Consider linaclotide for people with IBS only if:</b></p> <ul style="list-style-type: none"> <li>• optimal or maximum tolerated doses of previous laxatives from different classes have not helped and</li> <li>• they have had constipation for at least 12 months</li> </ul> <p><b>Follow-up people taking linaclotide after 3 months. [new 2015]</b></p> <p>The Committee agreed that the stated 'at least 12 months' indicates the severity of IBS, therefore it is not necessary to state</p>

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments Please insert each new comment in a new row.	Developer's Response Please respond to each comment
							'moderate' or 'severe'. There is not an internationally accepted definition of severity of IBS. .
SH	Almirall Ltd	2	Addendum	17	21	The wording regarding linaclotide should be consistent with the therapeutic indication. Suggest rewording to "Consider linaclotide for people with moderate or severe symptoms of IBS with constipation only if: 1) They have had IBS symptoms for at least 12 months and 2) optimal or maximum tolerated doses of laxatives have not helped"	Thank you for your comment. The Committee discussed this recommendation wording and made some amendments. The updated recommendation reads as follows:  <b>Consider linaclotide for people with IBS only if:</b> <ul style="list-style-type: none"> <li>• <b>optimal or maximum tolerated doses of previous laxatives from different classes have not helped and</b></li> <li>• <b>they have had constipation for at least 12 months</b></li> </ul> <b>Follow-up people taking linaclotide after 3 months. [new 2015]</b>  The Committee agreed that the stated 'at least 12 months' indicates the severity of IBS, therefore it is not necessary to state 'moderate' or 'severe'. There is not an internationally accepted definition of severity of IBS.
SH	Almirall Ltd	3	Addendum	22	9	Clarify use of linaclotide and benefits of treatment.  "Linaclotide, a guanylate cyclase C receptor agonist is one of a relatively new class of drugs for constipation with visceral analgesic and secretory benefits. Linaclotide is licenced for adults with moderate to severe IBS with constipation at a dose of 290µg once daily."	Thank you for the information. In the implementation of guidelines, clinicians are advised to look at the SPC where they will find this information. We do not duplicate information already in the SPC.  The effect of linaclotide on pain as a clinical

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response									
						Please insert each new comment in a new row.	Please respond to each comment									
						It is important that the visceral analgesic property of linaclotide is reflected in the new guideline (as stated in the SmPC), as abdominal pain is a key symptom in IBS patients.	outcome formed part of the main evidence review and this has been evaluated and discussed throughout the addendum.									
SH	Almirall Ltd	4	Addendum	29	42	<p>Concerns regarding the lack of data available for potential confounders were raised:</p> <p><i>“...Use of other medications e.g. anti-depressants, anti-spasmodics and analgesics, dietary fibre modification, fluid intake and exercise levels were not reported by study arm, leading to concerns about drug efficacy...”</i></p> <p>Concomitant Medication usage per study arm for the two phase III trials was balanced and did not serve as a confounding factor in favour of linaclotide:</p> <table><tr><th>Concomitant Medication</th><th>% of patients placebo</th><th>% of patients linaclotide</th></tr><tr><td>Bulking agents/Soluble fiber(A06AC)</td><td>2.26</td><td>3.11</td></tr><tr><td>Osmotic laxatives (A06AD)</td><td>0.5</td><td>0.5</td></tr></table> <p>Source data provided by Almirall Ltd.</p> <p>The general evaluation of the quality of the clinical evidence should be reviewed considering the additional data provided above. Page 29 of the guideline should be updated to reflect this assessment, as well as pages 265, 267, 268 and 269 of the addendum (see below).</p>	Concomitant Medication	% of patients placebo	% of patients linaclotide	Bulking agents/Soluble fiber(A06AC)	2.26	3.11	Osmotic laxatives (A06AD)	0.5	0.5	<p>Thank you for your comment. The included studies did not report whether concomitant medication use (particularly laxatives) or rescue medication use per study arm was balanced, therefore at the time of the evidence review we could not be confident that this was the case.</p> <p>This leads to uncertainty of the effect estimates and thus to the downgrading of the quality of evidence.</p> <p>The data subsequently provided during stakeholder consultation includes percentages only and no statistical comparisons are performed to evaluate differences between study arms.</p> <p>As such this additional data is insufficient to reduce our uncertainty of the evidence.</p> <p>Nevertheless, the Committee further discussed these recommendations and made some amendments as follows:</p> <p><b>Consider linaclotide for people with IBS only if:</b></p> <ul style="list-style-type: none"><li>• <b>optimal or maximum tolerated doses of previous laxatives from different classes have not helped and</b></li></ul>
Concomitant Medication	% of patients placebo	% of patients linaclotide														
Bulking agents/Soluble fiber(A06AC)	2.26	3.11														
Osmotic laxatives (A06AD)	0.5	0.5														

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments Please insert each new comment in a new row.	Developer's Response Please respond to each comment									
							<ul style="list-style-type: none"><li>they have had constipation for at least 12 months</li></ul> <b>Follow-up people taking linaclotide after 3 months. [new 2015]</b>									
SH	Almirall Ltd	5	Addendum	29	42	<p>Concerns regarding the lack of data available for potential confounders were raised.</p> <p>Use of rescue medication (other laxatives).</p> <p>Rescue medication usage per study arm for the two phase III trials did not serve as a confounding factor in favour of linaclotide:</p> <table><tr><td>Class of Rescue Medication</td><td>% of pts</td><td>% of pts</td></tr><tr><td></td><td>Placebo</td><td>Linaclotide</td></tr><tr><td>Stimulant Laxatives</td><td>75.16</td><td>56.27</td></tr></table> <p><i>Source data provided by Almirall Ltd.</i></p> <p>The general evaluation of the quality of the clinical evidence should be reviewed considering the additional data provided above. Page 29 of the guideline should be updated to reflect this assessment, as well as pages 265, 267, 268 and 269 of the addendum.</p>	Class of Rescue Medication	% of pts	% of pts		Placebo	Linaclotide	Stimulant Laxatives	75.16	56.27	<p>Thank you for your comment. The included studies did not report whether concomitant medication use (particularly laxatives) or rescue medication use per study arm was balanced, therefore at the time of the evidence review we could not be confident that this was the case.</p> <p>This leads to the uncertainty of the effect estimates and thus to the downgrading of the quality of evidence.</p> <p>The data subsequently provided during stakeholder consultation includes percentages only and no statistical comparisons are performed to evaluate differences between study arms.</p> <p>As such this additional data is insufficient to reduce our uncertainty of the evidence.</p> <p>Nevertheless, the Committee further discussed these recommendations and made some amendments as follows:</p> <p><b>Consider linaclotide for people with IBS only if:</b></p> <ul style="list-style-type: none"><li><b>optimal or maximum tolerated doses of previous laxatives from different classes have not helped and</b></li></ul>
Class of Rescue Medication	% of pts	% of pts														
	Placebo	Linaclotide														
Stimulant Laxatives	75.16	56.27														

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments Please insert each new comment in a new row.	Developer's Response Please respond to each comment
							<ul style="list-style-type: none"> <li><b>they have had constipation for at least 12 months</b></li> </ul> <b>Follow-up people taking linaclotide after 3 months. [new 2015]</b>
SH	Almirall Ltd	6	Addendum	31	2	<p>To make wording consistent throughout the guideline.</p> <p>Consider linaclotide for people with moderate or severe symptoms of IBS with constipation only if:</p> <p>1) They have had IBS symptoms for at least 12 months and</p> <p>2) optimal or maximum tolerated doses of laxatives have not helped. [2015]</p>	<p>This comment is a duplication of comment ID18 and 19 and suggests the addition of the word 'moderate' when describing constipation severity.</p> <p>After further discussion by the Committee, these recommendations have been amendments as follows:</p> <p><b>Consider linaclotide for people with IBS only if:</b></p> <ul style="list-style-type: none"> <li><b>optimal or maximum tolerated doses of previous laxatives from different classes have not helped and</b></li> <li><b>they have had constipation for at least 12 months</b></li> </ul> <p><b>Follow-up people taking linaclotide after 3 months. [new 2015]</b></p> <p>The Committee agreed that the stated 'at least 12 months' indicates the severity of IBS, therefore it is not necessary to state 'moderate' or 'severe'. There is not an internationally accepted definition of severity of IBS.</p> <p>Moreover, the 12-month time frame is based on the evidence (entry criteria from the included studies [Chey 2012; Rao 2012; Johnston 2010]).</p>

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response															
						Please insert each new comment in a new row.	Please respond to each comment															
SH	Almirall Ltd	7	Addendum	265	7 - 10	<p>Concerns regarding the lack of data available for potential confounders were raised.</p> <p>Concomitant Medication usage per study arm for the two phase III trials was balanced and did not serve as a confounding factor in favour of linaclotide:</p> <table><tr><td>Concomitant Medication (ATC Code)</td><td>% of patients placebo</td><td>% of patients linaclotide</td></tr><tr><td>Bulking agents/Soluble fibre (A06AC)</td><td>2.26</td><td>3.11</td></tr><tr><td>Osmotic laxatives (A06AD)</td><td>0.5</td><td>0.5</td></tr></table> <p><i>Source data provided by Almirall Ltd.</i></p> <p>Use of rescue medication (other laxatives):</p> <p>Rescue Medication usage per study arm for the two phase III trials (pooled analysis) was balanced and did not serve as a confounding factor:</p> <table><tr><td>Class of Rescue Medication</td><td>% of pts Placebo</td><td>% of pts linaclotide</td></tr><tr><td>Stimulant Laxatives</td><td>75.16</td><td>56.27</td></tr></table> <p><i>Source data provided by Almirall Ltd.</i></p> <p>.</p> <p>The general evaluation of the quality of the clinical evidence for linaclotide should be reviewed considering this additional data. Page 29 of the guideline should be updated to reflect this assessment, as well as pages 265, 267, 268 and 269 of the addendum.</p>	Concomitant Medication (ATC Code)	% of patients placebo	% of patients linaclotide	Bulking agents/Soluble fibre (A06AC)	2.26	3.11	Osmotic laxatives (A06AD)	0.5	0.5	Class of Rescue Medication	% of pts Placebo	% of pts linaclotide	Stimulant Laxatives	75.16	56.27	<p>Thank you for your comment. The included studies did not report whether concomitant medication use (particularly laxatives) or rescue medication use per study arm was balanced, therefore at the time of the evidence review we could not be confident that this was the case.</p> <p>This leads to the uncertainty of the effect estimates and thus to the downgrading of the quality of evidence.</p> <p>The data subsequently provided during stakeholder consultation includes percentages only and no statistical comparisons are performed to evaluate differences between study arms.</p> <p>As such this additional data is insufficient to reduce our uncertainty of the evidence.</p> <p>Nevertheless, the Committee further discussed these recommendations and made some amendments as follows:</p> <p><b>Consider linaclotide for people with IBS only if:</b></p> <ul style="list-style-type: none"><li>• <b>optimal or maximum tolerated doses of previous laxatives from different classes have not helped and</b></li><li>• <b>they have had constipation for at least 12 months</b></li></ul> <p><b>Follow-up people taking linaclotide after 3 months. [new 2015]</b></p>
Concomitant Medication (ATC Code)	% of patients placebo	% of patients linaclotide																				
Bulking agents/Soluble fibre (A06AC)	2.26	3.11																				
Osmotic laxatives (A06AD)	0.5	0.5																				
Class of Rescue Medication	% of pts Placebo	% of pts linaclotide																				
Stimulant Laxatives	75.16	56.27																				

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response															
						Please insert each new comment in a new row.	Please respond to each comment															
SH	Almirall Ltd	8	Addendum	267	2 - 3	<p>Concerns regarding the lack of data available for potential confounders were raised.</p> <p>Use of rescue medication (other laxatives):</p> <p>Rescue medication usage per study arm for the two phase III trials (pooled analysis) was balanced and did not serve as a confounding factor:</p> <table><tr><td>Class of Rescue Medication</td><td>% of pts Placebo</td><td>% of pts linaclotide</td></tr><tr><td>Stimulant Laxatives</td><td>75.16</td><td>56.27</td></tr></table> <p>Source data provided by Almirall Ltd.</p> <p>Concomitant Medication usage per study arm for the two phase III trials was balanced and did not serve as a confounding factor in favour of linaclotide:</p> <table><tr><td>Concomitant Medication (ATC Code)</td><td>% of patients placebo</td><td>% of patients linaclotide</td></tr><tr><td>Bulking agents/Soluble fibre (A06AC)</td><td>2.26</td><td>3.11</td></tr><tr><td>Osmotic laxatives (A06AD)</td><td>0.5</td><td>0.5</td></tr></table> <p>Source data provided by Almirall Ltd.</p> <p>.</p> <p>The general evaluation of the quality of the clinical evidence for linaclotide should be reviewed considering this additional data. Page 29 of the guideline should be updated to reflect this, as well as pages 265, 267, 268 and 269 of the addendum.</p>	Class of Rescue Medication	% of pts Placebo	% of pts linaclotide	Stimulant Laxatives	75.16	56.27	Concomitant Medication (ATC Code)	% of patients placebo	% of patients linaclotide	Bulking agents/Soluble fibre (A06AC)	2.26	3.11	Osmotic laxatives (A06AD)	0.5	0.5	<p>Thank you for your comment. The included studies did not report whether concomitant medication use (particularly laxatives) or rescue medication use per study arm was balanced, therefore at the time of the evidence review we could not be confident that this was the case.</p> <p>This leads to the uncertainty of the effect estimates and thus to the downgrading of the quality of evidence.</p> <p>The data subsequently provided during stakeholder consultation includes percentages only and no statistical comparisons are performed to evaluate differences between study arms.</p> <p>As such this additional data is insufficient to reduce our uncertainty of the evidence.</p> <p>Nevertheless, the Committee further discussed these recommendations and made some amendments as follows:</p> <p><b>Consider linaclotide for people with IBS only if:</b></p> <ul style="list-style-type: none"><li>• <b>optimal or maximum tolerated doses of previous laxatives from different classes have not helped and</b></li><li>• <b>they have had constipation for at least 12 months</b></li></ul> <p><b>Follow-up people taking linaclotide after 3 months. [new 2015]</b></p>
Class of Rescue Medication	% of pts Placebo	% of pts linaclotide																				
Stimulant Laxatives	75.16	56.27																				
Concomitant Medication (ATC Code)	% of patients placebo	% of patients linaclotide																				
Bulking agents/Soluble fibre (A06AC)	2.26	3.11																				
Osmotic laxatives (A06AD)	0.5	0.5																				

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response															
						Please insert each new comment in a new row.	Please respond to each comment															
SH	Almirall Ltd	9	Addendum	268	3 - 4	<p>Concerns regarding the lack of data available for potential confounders were raised.</p> <p>Use of rescue medication (other laxatives):</p> <p>Rescue medication usage per study arm for the two phase III trials (pooled analysis) was balanced and did not serve as a confounding factor:</p> <table><tr><td>Class of Rescue Medication</td><td>% of pts Placebo</td><td>% of pts linaclotide</td></tr><tr><td>Stimulant Laxatives</td><td>75.16</td><td>56.27</td></tr></table> <p>Source data provided by Almirall Ltd.</p> <p>Concomitant Medication usage per study arm for the two phase III trials was balanced and did not serve as a confounding factor in favour of linaclotide:</p> <table><tr><td>Concomitant Medication (ATC Code)</td><td>% of patients placebo</td><td>% of patients linaclotide</td></tr><tr><td>Bulking agents/Soluble fibre (A06AC)</td><td>2.26</td><td>3.11</td></tr><tr><td>Osmotic laxatives (A06AD)</td><td>0.5</td><td>0.5</td></tr></table> <p>Source data provided by Almirall Ltd.</p> <p>The general evaluation of the quality of the clinical evidence for linaclotide should be reviewed considering this additional data. Page 29 of the guideline should be updated to reflect this, as well as pages 265, 267, 268 and 269 of the addendum.</p>	Class of Rescue Medication	% of pts Placebo	% of pts linaclotide	Stimulant Laxatives	75.16	56.27	Concomitant Medication (ATC Code)	% of patients placebo	% of patients linaclotide	Bulking agents/Soluble fibre (A06AC)	2.26	3.11	Osmotic laxatives (A06AD)	0.5	0.5	<p>Thank you for your comment. The included studies did not report whether concomitant medication use (particularly laxatives) or rescue medication use per study arm was balanced, therefore at the time of the evidence review we could not be confident that this was the case.</p> <p>This leads to the uncertainty of the effect estimates and thus to the downgrading of the quality of evidence.</p> <p>The data subsequently provided during stakeholder consultation includes percentages only and no statistical comparisons are performed to evaluate differences between study arms.</p> <p>As such this additional data is insufficient to reduce our uncertainty of the evidence.</p> <p>Nevertheless, the Committee further discussed these recommendations and made some amendments as follows:</p> <p><b>Consider linaclotide for people with IBS only if:</b></p> <ul style="list-style-type: none"><li>• <b>optimal or maximum tolerated doses of previous laxatives from different classes have not helped and</b></li><li>• <b>they have had constipation for at least 12 months</b></li></ul> <p><b>Follow-up people taking linaclotide after 3 months. [new 2015]</b></p>
Class of Rescue Medication	% of pts Placebo	% of pts linaclotide																				
Stimulant Laxatives	75.16	56.27																				
Concomitant Medication (ATC Code)	% of patients placebo	% of patients linaclotide																				
Bulking agents/Soluble fibre (A06AC)	2.26	3.11																				
Osmotic laxatives (A06AD)	0.5	0.5																				

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.



Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response						
						Please insert each new comment in a new row.	Please respond to each comment						
SH	Almirall Ltd	10	Addendum	269	9 – 10	<p>Concerns regarding the lack of data available for potential confounders were raised.</p> <p>Use of rescue medication (other laxatives):</p> <p>Rescue medication usage per study arm for the two phase III trials (pooled analysis) was balanced and did not serve as a confounding factor:</p> <table><tr><td>Class of Rescue Medication</td><td>% of pts Placebo</td><td>% of pts linaclotide</td></tr><tr><td>Stimulant Laxatives</td><td>75.16</td><td>56.27</td></tr></table> <p><i>Source data provided by Almirall Ltd.</i></p> <p>The general evaluation of the quality of the clinical evidence for linaclotide should be reviewed considering this additional data. Page 29 of the guideline should be updated to reflect this, as well as pages 265, 267, 268 and 269 of the addendum.</p>	Class of Rescue Medication	% of pts Placebo	% of pts linaclotide	Stimulant Laxatives	75.16	56.27	<p>Thank you for your comment. The included studies did not report whether concomitant medication use (particularly laxatives) or rescue medication use per study arm was balanced, therefore at the time of the evidence review we could not be confident that this was the case.</p> <p>This leads to the uncertainty of the effect estimates and thus to the downgrading of the quality of evidence.</p> <p>The data subsequently provided during stakeholder consultation includes percentages only and no statistical comparisons are performed to evaluate differences between study arms.</p> <p>As such this additional data is insufficient to reduce our uncertainty of the evidence.</p> <p>Nevertheless, the Committee further discussed these recommendations and made some amendments as follows:</p> <p><b>Consider linaclotide for people with IBS only if:</b></p> <ul style="list-style-type: none"><li>• <b>optimal or maximum tolerated doses of previous laxatives from different classes have not helped and</b></li><li>• <b>they have had constipation for at least 12 months</b></li></ul> <p><b>Follow-up people taking linaclotide after 3 months. [new 2015]</b></p>
Class of Rescue Medication	% of pts Placebo	% of pts linaclotide											
Stimulant Laxatives	75.16	56.27											

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response
						Please insert each new comment in a new row.	Please respond to each comment
SH	British Acupuncture Council	1	General	General	General	There has been substantial new evidence on acupuncture and irritable bowel syndrome published since the original guideline, in particular the UK-based RCT from MacPherson et al (2012). Why then is acupuncture not part of the new evidence review in this addendum? The most recent meta-analysis (Chao and Zhang 2014) on the subject found a statistically significant beneficial effect. The adverse events data also need updating.	Thank you for your comment. Acupuncture for irritable bowel syndrome was outside the scope of this update. The review protocol specifies the interventions that were reviewed in this update. Your feedback will however be passed on to our surveillance team for the next review.
SH	British Dietetic Association	4	General	General	General	Should anything be included regarding assessing social circumstances/ understanding, before consideration of commencement of fodmap diet - to help improve adherence	Thank you for your comment. From the evidence point of view, none of the included studies for the low FODMAP diet mentioned social circumstances or level of understanding in their baseline characteristics, and therefore there is no evidence to support the suggestion that assessment would improve adherence. However, the Committee did acknowledge the importance of individual differences and patient-centred care, therefore the Committee has made a new recommendation that the dietary advice should <b><i>“only be given by a healthcare professional with expertise in dietary management”</i></b> , to ensure individual circumstances and understanding of the diet would be addressed. These may include the availability and choices of different food sources, as well as advice to implement the diet.
SH	British Dietetic Association	17	General	General	General	A very recent review indicates that NNT is 2.2 for a low FODMAP diet so it may be worth looking at this review paper for further details. Khan et al 2014 Low-FODMAP Diet for Irritable Bowel Syndrome: Is It Ready for Prime Time? Dig Dis Sci DOI 10.1007/s10620-014-3436-4	Thank you for the information. We have obtained and assessed this article but it doesn't meet the inclusion criteria of the systematic review as it is not a primary research study and it is not a systematic review of RCTs.

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments Please insert each new comment in a new row.	Developer's Response Please respond to each comment
SH	British Dietetic Association	18	Addendum	10		Change 'a healthcare professional' to a 'Registered Dietitian' – the research shows a low FODMAP diet to be successful when delivered by a Registered Dietitian	Thank you for your comment. This was discussed further by the Committee. They took into account your comments, as well as other differing comments from the British Gastroenterology Society. On balance, and the fact that this is a primary care guideline, the Committee agreed to keep the current recommendation because a dietitian is a healthcare professional with expertise in dietary management. The Committee felt they could not be more specific than the current recommendation.
SH	British Dietetic Association	9	Addendum	18	9	We would suggest that fermentation does not cause the symptoms of IBS. It worsens or provokes symptoms in patients with IBS who have visceral hypersensitivity	Thank you. We have made the suggested change in the addendum.
SH	British Dietetic Association	10	Addendum	18	18	We suggest '...with varying subtypes (diarrhoea predominant, ...)' would be more accurate than what is currently stated regarding the participants included in the studies.	Thank you. We have made the suggested change in the addendum.
SH	British Dietetic Association	11	Addendum	18	19	This is not entirely correct. This study included patients with bloating and diarrhoea, it was not specified that these were predominant symptoms, as suggested. The predominant symptom for each patient was not recorded in this study	Thank you. We have reworded as suggested in the addendum.
SH	British Dietetic Association	12	Addendum	19		Urgency was not considered in the evidence statement section. This is a major symptom that affects quality of life in these patients and should be included (measured in the controlled trial).	Thank you for your comment. We agree that this is a major symptom for some people with IBS. At the protocol development stage, the topic specific committee members were asked to identify and prioritise patient important outcomes. Examples of those identified include pain, overall symptoms, stool frequency and quality of life (full list is available in the review protocol). Urgency was not an outcome that was prioritised by the experts

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments Please insert each new comment in a new row.	Developer's Response Please respond to each comment
							hence it was not included in the review protocol. The evidence review only includes outcomes specified in the review protocol and the evidence statements can only reflect the evidence reviewed. As such it is not possible to consider urgency in the evidence statements.
SH	British Dietetic Association	13	Addendum	19	27	This population group did not have diarrhoea and/or bloating predominant IBS. The paper states that they experienced the symptom, not that it was predominant. Please note there was a significant change in satisfaction with bowel habit in both IBS-D and IBS-C in Halmos et al 2014. This was not mentioned in the evidence statements for diarrhoea and constipation.	<p>Thank you the wording has been amended and this point was verbally reiterated to the Committee.</p> <p>Patient satisfaction with bowel habit was not prioritised as an important outcome in the review protocol which is why this outcome is not mentioned in the evidence statement.</p>
SH	British Dietetic Association	16	Addendum	19		<p>The evidence statements for each symptom have been graded 'very low quality'. According to GRADE this means that any estimate of effect is very uncertain. All 3 studies considered report beneficial effects of the low FODMAP diet on symptoms.</p> <p>Certainly, there are limitations to the studies, including the lack of blinding, which is almost impossible in dietary intervention studies (Yao et al 2013, Design of Clinical Trials Evaluating Dietary Interventions in Patients With Functional Gastrointestinal Disorders, Gastroenterology)</p>	<p>Quality ratings for each outcome are rated based on 5 criteria. The GRADE profiles illustrate how the quality ratings were assigned and the corresponding footnotes provide the rationale for the judgement. GRADE methodology does not simply assess whether an intervention reported beneficial effects or not, it also assesses the certainty/uncertainty around the effect estimates from the included studies. These are 2 separate quality assessments.</p> <p>Thank you for your comment. We acknowledged that it is difficult to blind trials on dietary intervention. However, the impossibility to blind does not eliminate the potential placebo effects particularly if the outcomes are self-report measurements. The essence of GRADE is to be explicit and transparent.</p>

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments Please insert each new comment in a new row.	Developer's Response Please respond to each comment
						<p>For dietary intervention studies, the participant numbers are not particularly small and have been powered appropriately.</p> <p>GRADE recommends that grade should be increased if there is evidence of a dose response gradient. Please refer to Shepherd et al 2008 Dietary Triggers of Abdominal Symptoms in Patients With Irritable Bowel Syndrome: Randomized Placebo-Controlled Evidence. Clin Gastroenterol Hepatol 6:765–771 for a double blind quadruple arm placebo-controlled randomised controlled trial demonstrating a dose response effect for FODMAPs in inducing IBS symptoms.</p> <p>Finally, and importantly, studies should not be downgraded based on the statement that 'FODMAP diet usually advised for 8 weeks'. Clinical guidelines should be developed and graded based on the evidence, not on current practice.</p>	<p>The sample size of the included studies may be sufficient for testing a hypothesis (power-based sample size calculation); however it wasn't sufficient to be certain about the precision of the effect estimates (precision-based sample size calculation). Please refer to: <i>Bland M. BMJ 2009;339:b3985</i> <i>doi: 10.1136/bmj.b3985</i></p> <p>Thank you for your comment. In GRADE methodology, the criteria for upgrading only apply to observational studies if they have not been downgraded for any other reasons (based on the 4 criteria). This is explained fully <a href="#">here</a>.</p> <p>The paper you refer to (Shepherd 2008 was identified in our systematic review but was excluded (see F.33, P139) as it did not meet the inclusion criteria in the review protocol (the baseline was previous FODMAP responders rather than a comparison of low FODMAP diet with other diets).</p> <p>The evidence on specific outcomes was downgraded because the duration of the included studies meant that there was no data available on the reintroduction of low FODMAP diet or its long term effects.</p>
SH	British Dietetic	14	Addendum	20		As above. The Staudacher et al 2012 paper did not	Thank you this has been amended.

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response
	Association					Please insert each new comment in a new row. include IBS-D patients.	Please respond to each comment
SH	British Dietetic Association	15	Addendum	20		Regarding the statement 'the committee commented that the study period of these studies did not match current practice in the NHS...'  The purpose of the guidelines is to guide practice based on the evidence. Therefore, although I see consideration of current practice is important in this process, it should not influence the development of the guidelines.	Thank you for your comment. This statement is just a record of the discussion that took place. The evidence was downgraded because the duration of the included studies meant that there was no data available on reintroduction of low FODMAP diet or its long term effects.
SH	British Dietetic Association	1	NICE	16		Resistant starch is still in there???	Thank you for your comment. This section was not in the scope of this guideline update
SH	British Dietetic Association	6	NICE	16		Suggest amending the point around fibre in diet – there appears to be limited evidence for this	Thank you for your comment. This section was not in the scope of this guideline update
SH	British Dietetic Association	7	NICE	16 - 17		I welcome the inclusion of using the Low FODMAP exclusion diet as a next steps dietary intervention for those not responding to general diet and lifestyle advice. This may not be available to all ethnic backgrounds and minority groups, as current Low FODMAP resources available in the UK do not reflect the dietary foods common to some ethnic minorities and are only available in written English language.	Thank you for your comment. The issue of culturally specific foods for low FODMAP diet has been further discussed by the Committee. This has now being captured in the LETR table in the full addendum. The Committee acknowledged that the current dietary resources available for implementing the low FODMAP diet only includes a list of foods that are common in a typical western diet, and that information on culturally specific foods are very limited. Therefore, the Committee emphasized that healthcare professionals need to have an appropriate discussion with people with IBS who wish to go on a dietary intervention, particularly people who consumed culturally specific foods. Full information on available food sources for low FODMAP diet needs to be provided and discussed with people with IBS so that they can make an informed

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments Please insert each new comment in a new row.	Developer's Response Please respond to each comment
							decision.
SH	British Dietetic Association	8	NICE	17		The text... only be given by a healthcare professional with expertise in dietary management ...is ambiguous. The research thus far is based on advice provided by an experienced dietitian. Given the potential adverse effects on dietary intake of this exclusion diet, this should be specified as 'only be given by a dietitian'.	Thank you for your comment. This was discussed further by the Committee. The Committee took into account your comments, as well as other differing comments from the British Gastroenterology Society. On balance, and the fact that this is a primary care guideline, the Committee agreed to keep the current recommendation as a dietitian is a healthcare professional with expertise in dietary management. The Committee felt they could not be more specific than the current recommendation.
SH	British Dietetic Association	2	NICE	18	16	Space needed between 'this with'	Thank you, this has been done.
SH	British Dietetic Association	3	NICE	18	27	Space needed between 'with participants'	Thank you, this has been done.
SH	British Dietetic Association	5	NICE	21	1	Line 1: suggest adding the words recommend State Registered Dietitian	Thank you for your comment. This was discussed further by the Committee. The Committee took into account your comments, as well as other differing comments from the British Gastroenterology Society. On balance, and the fact that this is a primary care guideline, the Committee agreed to keep the existing recommendation as a dietitian is a healthcare professional with expertise in dietary management. The Committee felt they could not be more specific than current recommendations.
SH	British Pain Society	1	General	General	General	The British Pain Society welcomes the guidance as many patients with IBS also have other chronic pain conditions. The clarification regarding investigations, diagnosis and treatment is useful.	Thank you.

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response
						Please insert each new comment in a new row.	Please respond to each comment
SH	British Society of Gastroenterology	2	Addendum	13	13	<p>The committee has recommended that low dose TCA's and SSRI's should be considered as second line treatment for IBS patients that have not fully responded to laxatives, loperamide or anti-spasmodics. However, there is no recommendation for which type of IBS patient may benefit best from this treatment.</p> <p>There is no recommendation as to whether this should be taken as an additional medication (in addition to laxatives for instance). Could clarification be given?</p>	<p>Thank you for your comment.</p> <p>The committee did not recommend antidepressants as first line treatment due to the low quality evidence (See LETR table of addendum, p.16).</p> <p>Because there is insufficient new evidence to change current recommendations the Committee decided to carry forward the original guideline recommendations.</p> <p>There is also insufficient evidence on the use of antidepressants (TCAs and SSRIs) by IBS type, thus the recommendations do not make reference to IBS subtypes. (Of the 13 studies in the original full guideline, 6 identified IBS subtype as "mixed", the remainder did not specify. In this update, of the additional 4 studies that were reviewed, only one study reported outcomes by IBS subtype).</p> <p>There was no evidence identified on the use of antidepressants as monotherapy vs combination therapy. Therefore in the absence of clarity in the evidence, clinical judgement will need to be applied on a case-by-case basis.</p> <p>In addition, it is stated in the LETR table that of the 12 included studies, only 2 reported on the previous IBS treatment (one included participants who had previously failed to respond to anti-spasmodics n=107 and the other excluded those currently on antispasmodics n=81).</p> <p>Thank you for your support.</p>

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.



Type	Stakeholder	Order No	Document	Page No	Line No	Comments Please insert each new comment in a new row.	Developer's Response Please respond to each comment
						<p>We would support the committee's view to 're-launch' their support for further clinical research to support the case for the use of this class of drugs for the treatment of IBS.</p> <p>These comments are endorsed by the Royal College of Physicians.</p>	
SH	British Society of Gastroenterology	3	Addendum	19	General	<p>Data from limited trials of a low FODMAP diet in IBS is somewhat encouraging and anecdotal evidence is growing from NHS services but evidence to support the use of this intervention is still of low quality. Because of the increased interest of this dietary intervention both within the (predominantly) dietetic community and with IBS patients it is good that guidance is given.</p> <p>There are a few issues. The first is patient selection. It is not clear which type of IBS patient would benefit most from a low FODMAP diet but the best evidence suggests those with bloating and abdominal distension or those with proven intolerance to specific carbohydrate absorption would do best but this intervention maybe deleterious to IBS-C patients.</p>	<p>Thank you.</p> <p>Thank you for your comments. Your point regarding patient selection is well made. Having reviewed the evidence in full it was not possible to stratify data by IBS sub-groups for the outcome of bloating (nor any other outcomes) as this data was not available. Therefore, the Committee felt the recommendation could not be more specific based on current available evidence. The Committee would expect the clinical judgement of a qualified healthcare professional with expertise in dietary management to tailor dietary advice to the symptom profile of the individual, taking into account the physiological plausibility of the effects of the low FODMAP diet in different symptom profiles.</p>

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments Please insert each new comment in a new row.	Developer's Response Please respond to each comment
						<p>At present the guidance seems to suggest that a general diagnosis of IBS would be enough to merit a referral to a 'qualified healthcare professional' (presumably a dietician but the qualification is not specified) for administration of a low FODMAP diet.</p> <p>The question as to whether an IBS patient trying out the low FODMAP diet needs to see a trained healthcare professional any more than when being asked to try any other dietary intervention (such as low fibre for example) is up for debate. It is not clear that the low FODMAP diet poses any undue risks (as patients usually swap one type of fruits and vegetable for another equally healthy option, for example).</p> <p>There are excellent 'self-help' booklets / mobile phone</p>	<p>Thank you for your comment. We disagree with your interpretation as the beginning of the recommendation does clearly state: <i>If a person's IBS symptoms persist while following general lifestyle and dietary advice, offer advice on further dietary management...</i></p> <p>Hence, the current recommendation does not suggest that a general diagnosis of IBS would be enough to merit a referral to a 'qualified healthcare professional with expertise in dietary management'. The Committee felt that they could not be more specific about the qualification and job title because this should be commissioned and decided by local CCGs how they would want to set up local services.</p> <p>Thank you for your comments. As mentioned above, the recommendation as a whole covers other dietary components, requiring qualified healthcare professionals with expertise in dietary management, not just for the low FODMAP diet. The Committee discussed the lack of long term effects of low FODMAP diet (this is now captured in the LETR table). Due to this uncertainty, the Committee felt it's important to have the input from a qualified healthcare professional with expertise in dietary management. This qualified healthcare professional may or may not be</p>

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response
						Please insert each new comment in a new row.	Please respond to each comment
						<p>'apps' available to patients to try this diet initially and then could get a referral to a dietician upon review if unsuccessful or if they were finding it difficult to maintain nutritional balance.</p> <p>Introducing a dietician led primary care service would potentially increase costs and waiting times considerably and needs further justification with clinical trials. The committee have made a recommendation for further research in this area which we would strongly support.</p> <p>These comments are endorsed by the Royal College of Physicians.</p>	<p>a dietitian depending on local service configuration.</p> <p>The Committee were not convinced that current freely available self-help materials and 'apps' would be consistently high quality and have no assurance that they will have been properly developed and validated.</p> <p>Again, due to the uncertainty of the long term effects of low FODMAP diet, it is important to have input from a qualified healthcare professional with expertise in dietary management.</p> <p>Thank you for your comment. The current recommendation does not suggest introduction of a dietitian led primary care service.</p> <p>It will be down to local CCGs to decide how they want to commission services.</p> <p>Thank you.</p>
SH	British Society of Gastroenterology	1	Addendum	23	11	Lubiprostone is not a 5-HT4 agonist it is a chloride channel (CIC-2) agonist.	Thank you we have amended this.
SH	British Society of Gastroenterology	4	Addendum	23	General	Linacotide is a new class of drug which has been shown to effectively treat dual features (pain and bowel frequency) of IBS in a clearly defined (IBS-C) population	Thank you for your comment. A decision was made by the Committee not to make linacotide a first line treatment taking into

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response
	y					<p>Please insert each new comment in a new row.</p> <p>of patients. It is peripherally restricted and therefore has an excellent safety profile. The committee have recommended that Linaclotide should be available in primary care but only offered as an option when patient have been suffering from severe constipation for 12-months and have not responded to other laxatives. IBS-C is different to chronic constipation in several ways and by definition if patients IBS-C patients have had severe constipation for 12-months they will also have been suffering from abdominal pain for this period. It This seems like a very long period to make patients suffer and is at odds with guidance for prucalopride for instance which is 6-months. There does not seem to be a clear rationale as to why clinicians should wait for such a long period if there is an effective treatment available for a clearly defined sub-group of patients (unlike the majority of the other treatment options described).</p> <p>These comments are endorsed by the Royal College of Physicians.</p>	<p>Please respond to each comment</p> <p>account the uncertainty about the treatment effects, evidence quality and risk of bias (See LETR table, p29).</p> <p>It was also acknowledged that people with constipation would likely have tried multiple other laxatives already and thus a recommendation was made to offer linaclotide to people without sufficient symptom relief after twelve months. The 12-month time frame is based on the evidence available (the entry criteria from the included studies [Chey 2012; Rao 2012; Johnston 2010]).</p> <p>However this point has been discussed by the Committee. The Committee subsequently made some amendments to the recommendation wording but decided not to change the 12 month duration because it was evidence based. The updated recommendation is as follows:</p> <p><b>Consider linaclotide for people with IBS only if:</b></p> <ul style="list-style-type: none"> <li>• optimal or maximum tolerated doses of previous laxatives from different classes have not helped and</li> <li>• they have had constipation for at least 12 months</li> </ul> <p><b>Follow-up people taking linaclotide after 3 months. [new 2015]</b></p>

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response
						Please insert each new comment in a new row.	Please respond to each comment
SH	British Society of Gastroenterology	5	Addendum	33	General	<p>There is an extensive review of the use of different psychological interventions in IBS. Whilst the committee have not made any recommendations for the use of techniques such as relaxation therapy, Cognitive behavioural therapy and Mindfulness therapy due to lack of strong evidence, they have made a research recommendation for further work in this area to assess cost effectiveness which we would support.</p> <p>These comments are endorsed by the Royal College of Physicians.</p>	Thank you for your comment and support.
SH	British Society of Gastroenterology	6	Addendum	General	General	<p>Probiotics: There is growing evidence to suggest that dysbiosis in the GI tract contributes to IBS symptoms and that pro-biotic therapies can be effective but there is no review, update or research recommendations for this approach.</p> <p>These comments are endorsed by the Royal College of Physicians.</p>	Thank you for your comment. Probiotics were not in the scope for this update. Probiotics were evaluated in the original <a href="#">Full Guideline</a> (see section 7.4)
SH	British Society of Gastroenterology	7	Addendum	General	General	<p>Diagnostic testing: There is no update of the use of simple tests such as hydrogen and methane breath testing to identify patients with conditions such as small intestinal bacterial overgrowth or specific carbohydrate mal-absorption (and not IBS) which are cost effective and could provide objective evidence for inexpensive, targeted treatments.</p> <p>These comments are endorsed by the Royal College of Physicians.</p>	Thank you for your comment. Diagnostic testing for other conditions was outside the scope for this update.
SH	Department of Health	1	General	General	General	I wish to confirm that the Department of Health has no substantive comments to make, regarding this consultation.	Thank you.
SH	Digital Assessment Service, NHS Choices	1	General	General	General	DAS welcome the guidance and have no comments on its content.	Thank you.

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Type	Stakeholder	Order No	Document	Page No	Line No	Comments	Developer's Response
						Please insert each new comment in a new row.	Please respond to each comment
SH	NHS England	1	General	General	General	I wish to confirm that NHS England has no substantive comments to make regarding this consultation.	Thank you.
SH	Royal College of Nursing	1	General	General	General	Nurses working in this area have reviewed the addendum for the above guidelines and have no comments to submit.	Thank you.
SH	The Royal College of Pathologists	1	General	General	General	The Royal College of Pathologists does not have any comments on the following clinical addendum.	Thank you.

**These organisations were approached but did not respond:**

AbbVie  
 Alder Hey Children's NHS Foundation Trust  
 Allocate Software PLC  
 Alpha Laboratories Limited  
 Amgen UK  
 anglia community leisure  
 Anxiety UK  
 Association for Continence Advice  
 Association for Psychoanalytic Psychotherapy in the NHS  
 Association of Anaesthetists of Great Britain and Ireland  
 Association of British Healthcare Industries  
 Association of Child Psychotherapists, the  
 Association of Clinical Pathologists  
 Association of Coloproctology of Great Britain and Ireland  
 Association of Directors of Children's Services  
 B. Braun Medical Ltd  
 Belfast Health and Social Care Trust

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Birmingham & Brunel Consortium  
Bladder and Bowel Foundation  
Blood Pressure UK  
Boehringer Ingelheim  
Bradford District Care Trust  
British Acupuncture Council  
British Association for Counselling and Psychotherapy  
British Association for Parenteral & Enteral Nutrition  
British Association of Behavioural and Cognitive Psychotherapies  
British Geriatrics Society - Gastro-enterology and Nutrition Special Interest Group  
British Heart Foundation Health Promotion Research Group  
British Medical Association  
British Medical Journal  
British National Formulary  
British Nuclear Cardiology Society  
British Nuclear Medicine Society  
British Pharmacological Society  
British Psychological Society  
British Red Cross  
British Society of Gastroenterology  
British Society of Paediatric Gastroenterology Hepatology and Nutrition  
BSPGHAN  
BUPA Foundation  
Cambridge University Hospitals NHS Foundation Trust  
Camden Link  
Capsulation PPS  
Cardiff and Vale NHS Trust

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Care Quality Commission  
Central & North West London NHS Foundation Trust  
CHKS Ltd  
CIS' ters  
CLEAR Cannabis Law Reform  
Cochrane Depression Anxiety and Neurosis Group  
Coeliac UK  
Coloplast Limited  
Continence Advisory Service  
Covidien Ltd.  
Crohn's and Colitis UK  
Croydon Council  
Croydon University Hospital  
Cumbria Partnership NHS Foundation Trust  
CWHHE Collaborative CCGs  
David Lewis Centre, The  
Department for Communities and Local Government  
Department of Gastroenterology  
Department of Health, Social Services and Public Safety - Northern Ireland  
Ealing Hospital NHS Trust  
East and North Hertfordshire NHS Trust  
Equalities National Council  
Ethical Medicines Industry Group  
Faculty of Public Health  
Faculty of Sexual and Reproductive Healthcare  
Ferring Pharmaceuticals  
Fibroid Network Charity

**PLEASE NOTE: Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.**



Five Boroughs Partnership NHS Trust  
Forte Medical  
GE Healthcare  
George Eliot Hospital NHS Trust  
Gloucestershire County Council  
Gloucestershire Hospitals NHS Foundation Trust  
Gloucestershire LINK  
GP update / Red Whale  
Great Western Hospitals NHS Foundation Trust  
Greater Manchester & Beyond Coalition of PLW & HIV  
H & R Healthcare Limited  
Health and Care Professions Council  
  
Health and Social Care Information Centre  
Healthcare Improvement Scotland  
Healthcare Infection Society  
Healthcare Quality Improvement Partnership  
Healthwatch East Sussex  
Herts Valleys Clinical Commissioning Group  
Hindu Council UK  
Hockley Medical Practice  
HQT Diagnostics  
Humber NHS Foundation Trust  
Institute of Biomedical Science  
Institute of Psychiatry  
International Neuromodulation Society  
Johnson & Johnson  
Joint Royal Colleges Ambulance Liaison Committee

**PLEASE NOTE: Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.**

KCARE  
Kimal PLC  
Lactation Consultants of Great Britain  
Lancashire Care NHS Foundation Trust  
Leeds North Clinical Commissioning Group  
Local Government Association  
ME Association, The  
Medical Directorate Services  
Medicines and Healthcare products Regulatory Agency  
Mental Health Act Commission  
Ministry of Defence  
Muslim Doctors and Dentists Association  
National Clinical Guideline Centre  
National Collaborating Centre for Cancer  
National Collaborating Centre for Mental Health  
National Collaborating Centre for Women's and Children's Health  
National Deaf Children's Society  
National Institute for Health Research Health Technology Assessment Programme  
National Institute for Health Research  
National Patient Safety Agency  
National Pharmacy Association  
National Public Health Service for Wales  
Neuromodulation Society of the United Kingdom and Ireland  
Newham University Hospital NHS Trust  
NHS Barnsley Clinical Commissioning Group  
NHS Choices  
NHS Clinical Knowledge Summaries

**PLEASE NOTE: Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.**

NHS Connecting for Health  
NHS Derbyshire county  
NHS England  
NHS Hardwick CCG  
  
NHS Havering CCG  
NHS Health at Work  
NHS Improvement  
NHS Kirklees  
NHS Luton CCG  
NHS North Somerset CCG  
NHS Plus  
NHS Sheffield CCG  
NHS South Cheshire CCG  
NHS South Norfolk CCG  
NHS Wakefield CCG  
NHS Warwickshire North CCG  
NHS West Cheshire CCG  
Norgine Limited  
North of England Commissioning Support  
North West London Hospitals NHS Trust  
Northern Health and Social Care Trust  
Northern Ireland Chest, Heart & Stroke  
Northern Region Endoscopy Group  
Northwick Park and St Mark's Hospitals  
Nottingham City Hospital  
Novartis Pharmaceuticals  
Nursing and Midwifery Council

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.

Nutricia Advanced Medical Nutrition  
Nutrition and Diet Resources UK  
Obesity Action Campaign  
Ovarian Cancer Action  
Oxford Nutrition Ltd  
Oxfordshire Clinical Commissioning Group  
Pancreatic Cancer UK  
Pathfinders Specialist and Complex Care  
Peckforton Pharmaceuticals Ltd  
Pelvic Obstetric and Gynaecological Physiotherapy  
Pelvic Pain Support Network  
PERIGON Healthcare Ltd  
Pernicious Anaemia Society  
PharmaPlus Ltd  
Pilgrim Projects  
PrescQIPP NHS Programme  
Primary Care Pharmacists Association  
Primary Care Society for Gastroenterology  
Primary Care Society for Gastroenterology  
Primrose Bank Medical Centre  
PromoCon  
Public Health England  
Public Health Wales NHS Trust  
  
Quality Institute for Self Management Education and Training  
RioMed Ltd.  
Roche Products  
Royal Berkshire NHS Foundation Trust

**PLEASE NOTE: Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.**

Royal College of Anaesthetists  
Royal College of General Practitioners  
Royal College of General Practitioners in Wales  
Royal College of Midwives  
Royal College of Obstetricians and Gynaecologists  
Royal College of Paediatrics and Child Health  
Royal College of Paediatrics and Child Health , Gastroenterology, Hepatology and Nutrition  
Royal College of Pathologists  
Royal College of Physicians  
Royal College of Physicians of Edinburgh  
Royal College of Psychiatrists  
Royal College of Radiologists  
Royal College of Speech and Language Therapists  
Royal College of Surgeons of Edinburgh  
Royal College of Surgeons of England  
Royal Cornwall Hospitals NHS Trust  
Royal Free Hospital NHS Foundation Trust  
Royal Pharmaceutical Society  
Royal Society of Medicine  
Scottish Intercollegiate Guidelines Network  
SEE BETSI CADWALADR - North Wales NHS Trust  
Self Management UK  
Sheffield Children's Hospital  
Sheffield Children's NHS Trust  
Sheffield Teaching Hospitals NHS Foundation Trust  
Shire Pharmaceuticals Ltd  
SNDRI

**PLEASE NOTE: Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.**

Social Care Institute for Excellence  
Society and College of Radiographers  
Solvay  
South Eastern Health and Social Care Trust  
South London & Maudsley NHS Trust  
South West Yorkshire Partnership NHS Foundation Trust  
Southern Health & Social Care Trust  
St Mary's Hospital  
Staffordshire and Stoke on Trent Partnership NHS Trust  
Stockport Clinical Commissioning Group  
Symprove Ltd  
Teva UK  
The British Homeopathic Association & Faculty of Homeopathy 131134  
The British In Vitro Diagnostics Association  
  
The IBS Network  
The Neurological Alliance  
The Patients Association  
The Rotherham NHS Foundation Trust  
The University of Birmingham  
The Urology Trade Association  
UK Clinical Pharmacy Association  
University College London Hospital NHS Foundation Trust  
University Hospital Birmingham NHS Foundation Trust  
University Hospitals Birmingham  
University of Salford  
University of York  
Urology User Group Coalition

**PLEASE NOTE: Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.**

Warner Chilcott UK  
Welsh Government  
Welsh Scientific Advisory Committee  
West Midlands Ambulance Service NHS Trust  
Western Health and Social Care Trust  
Western Sussex Hospitals NHS Trust  
Whipps Cross University Hospital NHS Trust  
Worcestershire Acute Hospitals Trust  
Wyreside Products Ltd  
York Hospitals NHS Foundation Trust

**PLEASE NOTE:** Comments received in the course of consultations carried out by the Institute are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that the Institute has received, and are not endorsed by the Institute, its officers or advisory committees.